美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ablynx NV

52.87

0.0000

成交量：- -

成交額：- -

市值：4.16億

市盈率：-25.28

高：52.87

開：52.87

低：52.87

收：52.87

52周最高：55.29

52周最低：17.75

股本：786.16萬

流通股本：786.16萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0911

每股收益(LYR):-2.0911

淨資產收益率：--

總資產收益率：--

市淨率：2.01

市盈率(LYR):-25.28

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Ablynx NV

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.ablynx.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Ablynx Nv於2001年7月4日在比利時法律下成立為有限責任公司（naamloze vennootschap）。該公司是一家後期臨床生物製藥公司，利用其專有的納米抗體平台開發廣泛的未滿足的醫療需求的治療適應症。該公司認為，納米抗體是下一代蛋白質治療技術的領先者。該公司擁有超過45種專有和合作的納米抗體計劃，包括血液學，炎症，傳染病，自身免疫性疾病，腫瘤學和免疫腫瘤學。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ABLX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABLX\",,,,,undefined,":{"symbol":"ABLX","market":"US","secType":"STK","nameCN":"Ablynx NV","latestPrice":52.87,"timestamp":1529956800000,"preClose":52.87,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":7861635,"shares":7861635,"eps":-2.091075,"marketStatus":"未開盤","change":0,"latestTime":"06-25 16:00:00 EDT","open":52.87,"high":52.87,"low":52.87,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.091075,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1773907200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":52.87,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABLX\",,,,,undefined,":{"symbol":"ABLX","floatShares":7861635,"roa":"--","roe":"--","lyrEps":-2.091075,"shares":7861635,"dividePrice":0,"high":52.87,"amplitude":0,"preClose":52.87,"low":52.87,"week52Low":17.75,"pbRate":"2.01","week52High":55.29,"institutionHeld":0,"latestPrice":52.87,"eps":-2.091075,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.091075,"open":52.87,"prevYearClose":52.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABLX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABLX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ablynx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Ablynx Nv於2001年7月4日在比利時法律下成立為有限責任公司（naamloze vennootschap）。該公司是一家後期臨床生物製藥公司，利用其專有的納米抗體平台開發廣泛的未滿足的醫療需求的治療適應症。 該公司認為，納米抗體是下一代蛋白質治療技術的領先者。 該公司擁有超過45種專有和合作的納米抗體計劃，包括血液學，炎症，傳染病，自身免疫性疾病，腫瘤學和免疫腫瘤學。","exchange":"NASDAQ","name":"Ablynx NV","nameEN":"Ablynx NV"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ABLX\",market:\"US\",,,undefined,":null}}